Patents matching “formulation”

US 12251470

Lipid nanoparticle formulations

ARBUTUS BIOPHARMA CORPORATION · Granted Mar 18, 2025 · Expires Mar 13, 2045

US 12251378

Long-acting local anesthetic formulation

UNIVERSITY OF CONNECTICUT · Granted Mar 18, 2025 · Expires Mar 13, 2045

US 12246059

Stable hybrid FC fusion G-CSF formulation

ILKOGEN ILAÇ SANAYI VE TICARET A.S. · Granted Mar 11, 2025 · Expires Mar 6, 2045

US 12239687

Sustained release formulations using non-aqueous membrane emulsification

REGENERON PHARMACEUTICALS, INC. · Granted Mar 4, 2025 · Expires Feb 27, 2045

US 12233073

Skin care formulations and skin cancer treatment

Regents of the University of Minnesota · Granted Feb 25, 2025 · Expires Feb 20, 2045

US 12226456

Nasal powder formulation for treatment of hypoglycemia

Amphastar Pharmaceuticals, Inc. · Granted Feb 18, 2025 · Expires Feb 13, 2045

US 12220409

Roflumilast formulations with an improved pharmacokinetic profile

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Feb 11, 2025 · Expires Feb 6, 2045

US 12213985

Oral cannabinoid formulations

JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Feb 4, 2025 · Expires Jan 30, 2045

US 12213964

Isoxazoline parasiticide formulations

Tarsus Pharmaceuticals, Inc. · Granted Feb 4, 2025 · Expires Jan 30, 2045

US 12208069

Antibiofilm formulations

Arizona Board of Regents on Behalf of Northern Arizona University · Granted Jan 28, 2025 · Expires Jan 23, 2045

US 12201593

Oral pharmaceutical formulations of bitter compounds for asthma

Aardvark Therapeutics, Inc. · Granted Jan 21, 2025 · Expires Jan 16, 2045

US 12195773

PH20 polypeptide variants, formulations and uses thereof

HALOZYME, INC. · Granted Jan 14, 2025 · Expires Jan 9, 2045

US 12186384

Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens

The Regents of the University of Colorado, a Body Corporate · Granted Jan 7, 2025 · Expires Jan 2, 2045

US 12178861

Stabilized liquid and lyophilized ADAMTS13 formulations

Takeda Pharmaceutical Company Limited · Granted Dec 31, 2024 · Expires Dec 26, 2044

US 12178860

Hyaluronidase enzyme formulations for high volume administration

HALOZYME, INC. · Granted Dec 31, 2024 · Expires Dec 26, 2044

US 12180084

Cerium (III) carbonate formulations

The Regents of the University of California · Granted Dec 31, 2024 · Expires Dec 26, 2044

US 12173029

Antiviral prodrugs, pharmaceutical formulations, and methods

The Regents of the University of California · Granted Dec 24, 2024 · Expires Dec 19, 2044

US 12171750

Isoxazoline parasiticide formulations and methods for treating blepharitis

Tarsus Pharmaceuticals, Inc. · Granted Dec 24, 2024 · Expires Dec 19, 2044

US 12168013

Antiviral prodrugs and nanoformulations thereof

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Dec 17, 2024 · Expires Dec 12, 2044

US 12161643

Stable formulations of SHR0302

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Dec 10, 2024 · Expires Dec 5, 2044

US 12156897

Magnesium-containing oxytocin formulations and methods of use

TONIX PHARMA LIMITED · Granted Dec 3, 2024 · Expires Nov 28, 2044

US 12156883

Bisphosphocin gel formulations and uses thereof

Lakewood Amedex, Inc. · Granted Dec 3, 2024 · Expires Nov 28, 2044

US 12152262

PH20 polypeptide variants, formulations and uses thereof

HALOZYME, INC. · Granted Nov 26, 2024 · Expires Nov 21, 2044

US 12144812

Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators

Corcept Therapeutics Incorporated · Granted Nov 19, 2024 · Expires Nov 14, 2044